Recently, the Sodium Valproate Injection and Micuronium Chloride Injection, which were reported for production by Sichuan Creed Pharmaceuticals under the new registration classification, have entered the administrative examination and approval stage.
At present, no generic drugs have been approved for the listing of these two products in China.
According to data from Meinenet, the market size of sodium valproate in China's public medical institutions exceeds 2 billion yuan.
Micuronium chloride is a benzyl isoquinoline compound.
It is a highly selective, short-acting, non-depolarizing neuromuscular blocker.
It has the characteristics of quick recovery after action and can be used as an auxiliary drug for general anesthesia.
Relax the skeletal muscles to facilitate tracheal intubation and mechanical ventilation.
At present, only GlaxoSmithKline’s Micuronium Chloride injection is on sale in China.
It is a national health insurance category B product.
In recent years, it has been used in urban public hospitals, county-level public hospitals, urban community centers, and township health centers (referred to as China Public Medical Agency) terminal sales are not outstanding.
Production status of new classification of micuronium injection
Source: Mi Nei Net Consistency Evaluation Database
According to data from Minaiwang, two companies, Guangdong Jiabo Pharmaceutical and Sichuan Creed Pharmaceuticals, have submitted applications for the listing of micuronium chloride injections under the new classification.
Sichuan Creed Pharmaceuticals' products have entered the administrative examination and approval stage and are expected to win the first imitation.
Sodium valproate is a nitrogen-free broad-spectrum antiepileptic drug that can competitively inhibit Y-aminobutyric acid transaminase, and is effective for various types of minor seizures, myogenic epilepsy, localized grand mal seizures, grand mal seizures and mixed epilepsy.
, Clinically used for various epilepsy that other anti-epileptic drugs are ineffective.
According to data from Menet.
com, in 2019, the sales of terminal sodium valproate in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) exceeded 2 billion yuan, and the growth rate in the first half of 2020 declined slightly .
At present, the main varieties of sodium valproate on the market in China include sodium valproate for injection, sodium valproate sustained-release tablets, sodium valproate tablets, etc.
There is no sodium valproate injection on the market.
New classification of valproate injection
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
At present, many companies have submitted applications for the listing of sodium valproate injection with imitation of three categories.
Among them, the products of Hebei Renheyikang Pharmaceutical and Sichuan Creed Pharmaceutical have entered the administrative examination and approval stage.
Source: Minet database
Note: The statistics are as of March 25.
If there are any omissions, please correct me!